You are here: Home » News-CM » Companies » News
Business Standard

Glenmark Pharmaceuticals update on Phase 1 trail of Immuno-Oncology Agent GBR 1342

Capital Market 

Conducts first-in-human, open-label study for dosing of GBR 1342

Glenmark Pharmaceuticals announced that the first patient has been dosed in a Phase 1 trial of GBR 1342 (NCT03309111), an investigational bispecific antibody. This first-in-human, open-label study's primary objective is to assess the safety and tolerability of increasing doses of GBR 1342 in multiple myeloma patients until a maximum tolerated dose is reached. Additional study objectives include assessment of biomarkers, immunogenicity and additional measures of anti-tumor activity.

Powered by Capital Market - Live News

(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

First Published: Fri, December 08 2017. 09:08 IST
RECOMMENDED FOR YOU
RECOMMENDED FOR YOU